Recombinant antibodies: Towards a new generation of antivenoms?;Anticorps recombinants: Vers une nouvelle génération d'antivenins?

Journal de la Societe de Biologie

Volumn 200, Issue 4, 2006, Pages 345-354

  Aubrey, Nicolas ^a   Muzard, Julien ^b   Juste, Matthieu ^a   Billiald, Philippe ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN FRAGMENT; RECOMBINANT PROTEIN; SCORPION VENOM; VENOM ANTISERUM;

ANIMAL; ANTIBODY SPECIFICITY; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; PROTEIN CONFORMATION; REVIEW;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIVENINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SCORPION VENOMS;

ANIMALIA; MUS; SCORPIONES;

EID: 34547633100     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2006038     Document Type: Review

References (48)

1. Alvarez-Rueda N., Behar G., Ferré V., Pugnière M., Roquet F., Gastinel L., Jacquot C., Aubry J., Baty D., Barbet J. & Birklé S., Generation of llama single-chain antibodies against methotrexate, a prototypical hapten. Mol. Immunol., 2007, 44, 1691-1701.
2. Aubrey N., Devaux C., di Luccio E., Goyffon M., Rochat H. & Billiald P., A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin AahI. Biol. Chem., 2001, 382, 1621-1628.
3. Aubrey N., Devaux C., Sizaret P. Y., Rochat H., Goyffo M. & Billiald P., Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. Cell. Mol. Life Sci., 2003, 60, 617-628.
4. Aubrey N., Muzard J., Peter J. C., Rochat H., Goyffon M., Devaux C. & Billiald P., Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments. Toxicon, 2004, 43, 233-241.
5. Aujame L., Geoffroy F. & Sodoyer R., High affinity human antibodies by phage display. Hum. Antibodies, 1997, 8, 155-168.
6. Bahraoui E., Pichon J., Muller J. M., Darbon H., El Ayeb M., Granier C., Marvaldi J. & Rochat H., Monoclonal antibodies to scorpion toxins. Characterization and molecular mechanisms of neutralization. J. Immunol., 1988, 141, 214-220.
7. Bon C., Serum therapy was discovered 100 years ago. 1996. Lyon, France, Fondation Marcel Merieux.
8. Bruggemann M. & Taussig M. J., Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol., 1997, 8, 455-458.
9. Brygoo E. R., La découverte de la sérothérapie antivenimeuse en 1894. Phisalix et Bertrand ou Calmette. Bull. Assoc. Anciens Elèves Inst. Pasteur, 1985, 106, 10-22.
10. Cao Y. & Lam B., Bispecific antibody conjugates in therapeutics. Adv. Drug Deliv. Rev., 2003, 55, 171-197.
11. Carrier A., Ducancel F., Settiawan N. B., Cattolico L., Maillere B., Leonetti M., Drevet P., Menez A. & Boulain J. C., Recombinant antibody-alkaline phosphatase conjugates for diagnosis of human IgGs: application to anti-HBsAg detection. J. Immunol. Methods, 1995, 181, 177-186.
12. Casadevall A. & Scharff M. D., Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother, 1994, 38, 1695-1702.
13. Chapman A. P., PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev, 2002, 54, 531-545.
14. Chippaux J. P. & Goyffon M., Antivenom serotherapy: its applications, its limitations, its future. Bull. Soc. Pathol. Exot., 1991, 84, 286-297.
15. Clot-Faybesse O., Juin M., Rochat H. & Devaux C., Monoclonal antibodies against the Androctonus australis hector scorpion neurotoxin I: characterisation and use for venom neutralisation. FEBS Lett., 1999, 458, 313-318.
16. Devaux C., Jouirou B., Krifi M. N., Clot-Faybesse O., El Ayeb M. & Rochat H., Quantitative variability in the biodistribution and in toxinokinetic studies of the three main alpha toxins from the Androctonus australis hector scorpion venom. Toxicon, 2004, 43, 661-669.
17. Devaux C., Moreau E., Goyffon M., Rochat H. & Billiald P., Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur. J. Biochem., 2001, 268, 694-702.
18. Dubreuil O., Muller B., Bossus M., Savatier A. & Ducancel F., Évolution moléculaire dirigée d'anticorps. J. Soc. Biol. 2006, 200 (4), 355-363.
19. Fanger M. W., Morganelli P. M. & Guyre P. M., Bispecific antibodies. Crit. Rev. Immunol., 1992, 12, 101-124.
20. Gazarian K. G., Gazarian T., Hernandez R. & Possani L. D., Immunology of scorpion toxins and perspectives for generation of anti-venom vaccines. Vaccine, 2005, 23, 3357-3368.
21. Ghalim N., El-Hafny B., Sebti F., Heikel J., Lazar N., Moustanir R. & Benslimane A., Scorpion envenomation and serotherapy in Morocco. Am. J. Trop. Med. Hyg., 2000, 62, 277-283.
22. Goldman E. R., Anderson G. P., Liu J. L., Delrhanty J. B., Shrwood L. J., Osborn L.E., Cummins L.B. & Hayhurst, A., Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal. Chem., 2006, 78, 8245-8255.
23. Harrison R. A., Hasson S. S., Harmsen M., Laing G. D., Conrath K. & Theakston R. D., Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon, 2006, 47, 364-368.
24. Holliger P. & Hudson P. J., Engineered antibody fragments and the rise of single domains. Nat. Biotechnol., 2005, 23, 1126-1136.
25. Holliger P. & Winter G., Engineering bispecific antibodies. Curr. Opin. Biotechnol., 1993, 4, 446-449.
26. Hwang W. Y. & Foote J., Immunogenicity of engineered antibodies. Methods, 2005, 36, 3-10.
27. Juarez-Gonzalez V. R., Riano-Umbarila L., Quintero-Hernandez V., Olamendi-Portugal T., Ortiz-Leon M., Ortiz E., Possani L. D. & Becerril B., Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J. Mol. Biol., 2005, 346, 1287-1297.
28. +-channel toxins protects against experimental scorpion envenoming. Cell. Mol. Life Sci., 2007, 64, 206-218.
29. Kashmiri S. V., De Pascalis R., Gonzales N. R. & Schlom J., SDR grafting - a new approach to antibody humanization. Methods, 2005, 36, 25-34.
30. Kim S. J., Park Y. & Hong H. J., Antibody engineering for the development of therapeutic antibodies. Mol. Cells, 2005, 20, 17-29.
31. Kipriyanov S. M., Moldenhauer G., Braunagel M., Reusch U., Cochlovius B., Le Gall F., Kouprianova O. A., Von der Lieth C. W. & Little M., Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol., 2003, 330, 99-111.
32. Korn T., Nettelbeck D. M., Volkel T., Muller R. & Kontermann R. E., Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J. Gene Med., 2004, 6, 642-651.
33. Kortt A. A., Lah M., Oddie G. W., Gruen C. L., Burns J. E., Pearce L. A., Atwell J. L., McCoy A. J., Howlett G. J., Metzger D. W., Webster R. G. & Hudson P. J., Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing fiveand ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng., 1997, 10, 423-433.
34. Krifi M. N., Amri F., Kharrat H. & El Ayeb M., Evaluation of antivenom therapy in children severely envenomed by Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot) scorpions. Toxicon, 1999, 37, 1627-1634.
35. Krifi M. N., El Ayeb M. & Dellagi K., New procedures and parameters for better evaluation of Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot) scorpion envenomations and specific serotherapy treatment. Toxicon, 1996, 34, 257-266.
36. Licea A. F., Becerril B. & Possani L. D., Fab fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole soluble venom from the scorpion Centruroides noxius Hoffmann. Toxicon, 1996, 34, 843-847.
37. Martin M. F. & Rochat H., Large scale purification of toxins from the venom of the scorpion Androctonus australis Hector. Toxicon, 1986, 24, 1131-1139.
38. Meddeb-Mouelhi F., Bouhaouala-Zahar B., Benlasfar Z., Hammadi M., Mejri T., Moslah M., Karoui H., Khorchani T. & El Ayeb M., Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon, 2003, 42, 785-791.
39. Mousli M., Devaux C., Rochat H., Goyffon M. & Billiald P., A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. FEBS Lett., 1999, 442, 183-188.
40. Pepin-Covatta S., Lutsch C., Grandgeorge M., Lang J. & Scherrmann J. M., Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions. Toxicol. Appl. Pharmacol., 1996, 141, 272-277.
41. Possani L. D., The past, present, and future of biotechnology in Mexico. Nat. Biotechnol., 2003, 21, 582-583.
42. Quintero-Hernandez V., Juarez-Gonzalez V. R., Ortiz-Leon M., Sanchez M., Possani L. D. & Becerril B., The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol. Immunol., 2007, 44, 1307-1315.
43. Reichert J. M., Rosensweig C. J., Faden L. B. & Dewitz M. C., Monoclonal antibody successes in the clinic. Nat. Biotechnol., 2005, 23, 1073-1078.
44. Riano-Umbarila L., Juarez-Gonzalez V. R., Olamendi-Portugal T., Ortiz-Leon M., Possani L. D. & Becerril B., A strategy for the generation of specific human antibodies by directed evolution and phage display. An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom. Febs J., 2005, 272, 2591-2601.
45. Selisko B., Cosio G., Garcia C., Becerril B., Possani L. D. & Horjales E., Bacterial expression, purification and functional characterization of a recombinant chimeric Fab derived from murine mAb BCF2 that neutralizes the venom of the scorpion Centruroides noxius hoffmann. Toxicon, 2004, 43, 43-51.
46. Staelens S., Desmet J., Ngo T. N., Vauterin S., Pareyn I., Barbeaux P., Van Rompaey I., Stassen J. M., Deckmyn H. & Vanhoorelbeke K., Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol. Immunol., 2006, 43, 1243-1257.
47. Theakston R. D., Warrell D. A. & Griffiths E., Report of a WHO workshop on the standardization and control of antivenoms. Toxicon, 2003, 41, 541-557.
48. WHO, Progress in the characterization of venoms and standardization of antivenoms., WHO, 1981, Geneva.